The Value of Our Medicines
We don't just believe that innovation is critical to the development of our medicines. Amgen also seeks to drive innovation in the way that our medicines are created, reimbursed and accessed by the patients who need them most. That's why we're working to:
- Provide cost-effective solutions, including biosimilars, for patients around the globe
- Evolve manufacturing processes to drive down costs
- Develop advanced new technologies to engage patients and providers to ensure optimal value is derived from our products
- Foster partnerships with payers to improve overall population health to ensure we are delivering our medicines to the patients who need them most
- Accelerate discovery and development of new medicines through clinical trial efficiencies
- Continue to be a leading manufacturer of high-quality and reliably supplied medicines
As a science-led company, Amgen is committed to developing and delivering high quality, targeted medicines that make a difference to patients’ lives and address some of society’s most devastating and grievous illnesses.
Our objective as an organization is aligned with that of any healthcare system – to improve the health of the populations we serve, and to deliver healthcare solutions that help individuals lead longer, healthier and more productive lives. Our innovative medicines and healthcare solutions improve patient productivity and quality of life, while helping to reduce healthcare and societal costs, such as medical spending, hospital costs and physician office visit expenditures.
We believe that the price of a medicine should reflect the holistic economic value delivered to patients, providers and payers, the unmet medical need, the size of the patient population and be aligned with the investment and risk Amgen undertakes to develop medicines as well as fund future scientific innovation.
To create a sustainable healthcare system, all stakeholders must recognize that the overall economic burden of disease will make health care costs unsustainable, and that innovative medicines are part of the solution and not the problem. At Amgen, we are committed to an ongoing dialogue with patients, providers, payers, policymakers and regulators to find ways to promote innovation, while also alleviating the financial and societal burden of some of the world’s most serious diseases.
Joshua J. Ofman, MD, MSHS Senior Vice President, Global Value, Access and Policy at Amgen Talks About Value
Video: Health Evolution Summit Panel Discussion - "Building the Business Case for High-Priced Therapeutics”
Video: Financial Times Panel Discussion - "Pricing and Reimbursement: Surviving and Thriving in a Value Based World"
Amgen's commitment to innovation has led us to launch groundbreaking therapies to treat serious illnesses. To ensure we meet the needs of patients who can benefit from our medicines worldwide, Amgen is committed to producing safe and effective therapies that can be appropriately accessed by the patients who need them most.